Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer

Author:

Møller Pål1,Reis Marta M.2,Evans Gareth3,Vasen Hans4,Haites Neva5,Anderson Elaine6,Steel C. Michael6,Apold Jaran7,Lalloo Fiona3,Mæhle Lovise1,Preece Paul2,Gregory Helen5,Heimdal Ketil1,

Affiliation:

1. Unit of Medical Genetics, The Norwegian Radium Hospital, N-0310 Oslo, Norway

2. Departments of Surgery and Genetics, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK

3. Family History Clinic, Centre for Cancer Epidemiology, Christie Hospital NHS Trust, Withington, Manchester M20 4QL, UK

4. The Netherlands Foundation for the Detection of Hereditary Tumours, c/o University Hospital, Rijnsburgerweg 10, Building no 5, 2333 AA Leiden, The Netherlands

5. Department of Medical Genetics, University of Aberdeen, Polworth Building, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK

6. Family History Clinic, Breast Screening Centre, Ardmillan Terrace, Edinburgh EH11 2JL, Scotland, UK

7. Department of Medical Genetics, Haukeland University Hospital, N-5521 Bergen, Norway

Abstract

BACKGROUND: Surveillance programmes for women at increased genetic risk of breast cancer are being established worldwide but little is known of their efficacy in early detection of cancers and hence reduction in mortality.METHODS: Data were contributed from seven centres participating in the EU Demonstration Programme on Clinical Services for Familial Breast Cancer. All breast tumours (n = 161) detected prospectively, from the time of enrolment of women in a screening programme, were recorded. Analysis took account of age at diagnosis, whether tumours were screen-detected or not, their pathological stage and outcome by Kaplan—Meier survival plots.RESULTS: Mean age at diagnosis was 48.6 years. Overall, 75% of tumours were detected in the course of planned examinations. For women under age 50 at diagnosis, this figure was 68%. Eighteen percent were mammographically negative, (23% in patients under age 50). At first (“prevalence”) round and at follow-up screening, 16% and 22% of tumours respectively were carcinoma in situ (CIS) while 27% and 22% respectively had evidence of nodal or distant spread (CaN+). Comparison of screen-detected and other tumours showed that the latter were more frequently mammogram-negative and CaN+. Overall five-year survival was 89% and five-year event-free survival 86%. Five-year event-free survival was 100% for CIS, 88% for invasive cancer without nodal or distant spread and 67% for CaN+.CONCLUSIONS: The majority of cancers arising in women at increased genetic risk of breast cancer can be detected by planned screening, even in those under age 50. Surveillance should include regular expert clinical examination and teaching of “breast awareness” as well as mammography. Attention to the logistics of screening programmes may improve still further the proportion of tumours that are screen-detected. The trend towards earlier pathological stage in tumours detected during follow-up rounds and the preliminary findings on survival analysis suggest that this approach will prove to be of long-term benefit for breast cancer families.

Funder

EU Biomed 2 Program

Publisher

Hindawi Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics,Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3